Publications by authors named "Christopher Allen Berger"
Background: Digital adherence technologies have been widely promoted as a means to improve tuberculosis medication adherence. However, uptake of these technologies has been suboptimal by both patients and health workers. Not surprisingly, studies have not demonstrated significant improvement in treatment outcomes.
View Article and Find Full Text PDFStudy protocol and implementation details for a pragmatic, stepped-wedge cluster randomised trial of a digital adherence technology to facilitate tuberculosis treatment completion.
Rebecca Crowder Alex Kityamuwesi Noah Kiwanuka Maureen Lamunu Catherine Namale Christopher Allen Berger
BMJ Open
November 2020
Article Synopsis
- Low-cost digital adherence technologies (DATs), like 99DOTS, are being tested as alternatives to directly observed therapy (DOT) for supervising tuberculosis (TB) treatment, focusing on the effectiveness and implementation of 99DOTS in Uganda.
- The trial involves around 1,890 adults with drug-susceptible pulmonary TB over eight months, with sites transitioning from DOT to 99DOTS in a staggered manner to evaluate treatment completion rates.
- Ethics approval has been obtained, and results will be shared through publications and presentations to relevant stakeholders to inform future TB treatment practices.